Abstract 16779: A Novel Hydrogen Sulfide Donor Promotes Nitric Oxide Bioavailability in a Phase I Clinical Trial

Introduction: Recent studies suggest molecular crosstalk between hydrogen sulfide (H2S) and nitric oxide (NO), although the mechanisms remain poorly understood. Heart failure patients have been reported to be deficient of both H2S and NO, two molecules that are critical for cardiovascular homeostasis. A Phase I clinical trial of a highly novel H2S donor agent (SG-1002) sought to assess the safety of SG-1002 as well as the effects of this drug on H2S and NO bioavailability in healthy subjects. Methods: 7 healthy male subjects were given SG-1002 orally in dosages ranging from 200-800 mg/kg twice daily for 7d. Plasma samples were collected at incremental time points during a 24hr. period. H2S levels were determined using gas chromatography coupled with sulfur chemiluminescence (7890B and 355 SCD, Agilent Tech.). NO bioavailability was determined by measuring the NO intermediate, nitrite (NO2), using ion chromatography (ENO-30, EICOM USA). Results: Administration of SG-1002 at the 800 mg/kg, b.i.d. dosage in ...